Bayer And Orion Join Efforts To Test ODM-201In A New Phase 3 Prostate Cancer Trial

Bayer And Orion Join Efforts To Test ODM-201In A New Phase 3 Prostate Cancer Trial
Bayer HealthCare and Orion Corporation recently announced that they have started enrolling patients in a Phase III trial to study ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. ARAMIS is a randomized, Phase III, multicenter, double-blind, placebo-controlled trial that will evaluate ODM-201 in

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *